Abstract
This case further suggests that levodopa/benserazide during pregnancy is safe in the treatment of PRKN-associated Young-Onset Parkinson’s Disease (YOPD).
Introduction
Parkinson’s Disease (PD) is traditionally viewed as a geriatric condition, with the average age of onset around 60. However, approximately 5% of patients develop symptoms before age 40, a category known as Young-Onset Parkinson’s Disease (YOPD). Because YOPD affects individuals during their reproductive years, clinicians face a significant challenge: balancing the mother’s need for motor control with the potential teratogenic risks of anti-PD medications. This paper provides clinical data by documenting the genetic profile, treatment regimen, and long-term outcomes for a 30-year-old Chinese woman with PRKN-associated YOPD.
Case Presentation and Genetic Analysis
The patient, a 36-year-old woman, presented with an 18-year history of motor symptoms. To identify the underlying cause, researchers performed complete exome sequencing (CES) on the patient and her parents. The analysis identified a homozygous mutation of p.G284R (c.850G > C) in exon 7 of the PRKN gene. The mutation was traced back to a consanguineous marriage, confirming an autosomal recessive inheritance pattern.
Clinical Course and Management
The patient's clinical history shows a progression from initial symptoms at age 18 to a formal diagnosis and subsequent management through pregnancy.
During the first trimester, the patient was treated with low-dose levodopa/benserazide (100/25 mg twice daily). A striking observation occurred during the 16th week of gestation: the patient’s motor symptoms significantly improved, with her UPDRS III score dropping from 16 to 6. This improvement allowed her to stop medication entirely for a period. Researchers hypothesize that rising estrogen levels during pregnancy may exert a neuroprotective effect on dopaminergic neurons.
Outcomes and Discussion
The patient delivered a healthy baby boy at 32 weeks via uncomplicated vaginal delivery. While the delivery was premature, it was attributed to cervical incompetence rather than PD or its treatment. At a 6-year follow-up, the child showed normal neurological development, suggesting no long-term adverse effects from in-utero exposure to low-dose levodopa/benserazide.
Two weeks after delivery, the patient’s symptoms aggravated, requiring a return to her medication regimen. This suggests that the protective physiological state of pregnancy is transient and requires close neurological supervision post-partum. While this case supports the safety of levodopa, the authors caution that other anti-PD drugs, such as amantadine, should be avoided due to known malformation risks. Future work should focus on establishing larger international registries to track pregnancy outcomes in PD patients and further investigate the hormonal mechanisms influencing dopaminergic pathways.
Summary updated